BenevolentAI

BenevolentAI is a clinical-stage AI drug discovery company that uses its proprietary Benevolent Platform to identify novel drug targets and develop therapeutic candidates. The platform combines a massive biomedical knowledge graph with machine learning models to find hidden connections between diseases, genes, and potential drug molecules.

The company's knowledge graph integrates data from scientific literature, clinical trials, patents, and molecular databases to create a comprehensive map of biological relationships. AI models then traverse this graph to identify previously unknown drug targets and predict which therapeutic approaches are most likely to succeed in clinical trials.

BenevolentAI went public on the Amsterdam Euronext exchange and has drug candidates in clinical development, including programs in atopic dermatitis and ulcerative colitis. The company notably used its AI platform to identify baricitinib as a potential COVID-19 treatment early in the pandemic, which was subsequently validated in clinical trials.